{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:00:46Z","timestamp":1775844046536,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbrc.2025.152360","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:27:55Z","timestamp":1752906475000},"page":"152360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice"],"prefix":"10.1016","volume":"778","author":[{"given":"J. Jose","family":"Corbalan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda A.","family":"Petronella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7650-0570","authenticated-orcid":false,"given":"Chia-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7283-5394","authenticated-orcid":false,"given":"James R.","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin B.","family":"Mugrage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9984-3056","authenticated-orcid":false,"suffix":"Jr.","given":"Joseph T.","family":"Nickels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152360_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Collaboration","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.152360_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.bbrc.2025.152360_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-023-00435-4","article-title":"Child and adolescent obesity","volume":"9","author":"Lister","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2025.152360_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41387-024-00352-9","article-title":"Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being","volume":"14","author":"Dall","year":"2024","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.bbrc.2025.152360_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pcad.2018.06.003","article-title":"Metabolic and bariatric surgery: an effective treatment option for obesity and cardiovascular disease","volume":"61","author":"English","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bbrc.2025.152360_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152360_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.152360_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152360_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152360_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/HCO.0000000000001214","article-title":"Advances in the management of obesity and heart failure: latest evidence from clinical trials","author":"Costa","year":"2025","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.bbrc.2025.152360_bib11","article-title":"FDA approves semaglutide to reduce risk of kidney disease progression","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.152360_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2025.152360_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152360_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70080","article-title":"Analysis of reporting trends of serious adverse events associated with anti-obesity drugs","volume":"13","author":"Raicevic","year":"2025","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bbrc.2025.152360_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2025.152360_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.152360_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1194\/jlr.R052902","article-title":"Intestinal triacylglycerol synthesis in fat absorption and systemic energy metabolism","volume":"56","author":"Yen","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0163-7827(03)00051-1","article-title":"Enzymes of triacylglycerol synthesis and their regulation","volume":"43","author":"Coleman","year":"2004","journal-title":"Prog. Lipid Res."},{"issue":"Suppl 2","key":"10.1016\/j.bbrc.2025.152360_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diab.41.2.S97","article-title":"Role of cytokines in inducing hyperlipidemia","volume":"41","author":"Feingold","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.152360_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000514848","article-title":"Triglycerides mediate body mass index and nonalcoholic fatty liver disease: a population-based study","volume":"14","author":"Xing","year":"2021","journal-title":"Obes. Facts"},{"key":"10.1016\/j.bbrc.2025.152360_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243068","article-title":"The association between triglycerides and ectopic fat obesity: an inverted U-shaped curve","volume":"15","author":"Zou","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152360_bib22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Piche","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","article-title":"Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis","volume":"49","author":"Yen","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib25","doi-asserted-by":"crossref","first-page":"18532","DOI":"10.1074\/jbc.M301633200","article-title":"MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine","volume":"278","author":"Yen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib26","doi-asserted-by":"crossref","first-page":"28237","DOI":"10.1074\/jbc.M114.571190","article-title":"Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis","volume":"289","author":"Jin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib27","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1038\/s41598-022-08946-y","article-title":"The monoacylglycerol acyltransferase pathway contributes to triacylglycerol synthesis in HepG2 cells","volume":"12","author":"McFie","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.152360_bib28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm.1937","article-title":"Deficiency of the intestinal enzyme acyl coa:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding","volume":"15","author":"Yen","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2025.152360_bib29","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1021\/acs.jmedchem.8b00864","article-title":"Monoacylglycerol acyltransferase 2 (MGAT2) inhibitors for the treatment of metabolic diseases and nonalcoholic steatohepatitis (NASH)","volume":"61","author":"Devasthale","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2015.03.072","article-title":"JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity","volume":"758","author":"Okuma","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152360_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/2211-5463.12778","article-title":"Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob\/ob mice fed on a high-fat diet","volume":"10","author":"Mochida","year":"2020","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbrc.2025.152360_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150976","article-title":"Pharmacological inhibition of monoacylglycerol O-Acyltransferase 2 improves hyperlipidemia, obesity, and diabetes by change in intestinal fat utilization","volume":"11","author":"Take","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.152360_bib33","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.cmet.2022.10.007","article-title":"MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity","volume":"34","author":"Cheng","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1194\/jlr.P025536","article-title":"Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver","volume":"53","author":"Hall","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib35","doi-asserted-by":"crossref","first-page":"41838","DOI":"10.1074\/jbc.M111.245456","article-title":"Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases","volume":"286","author":"Cao","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1194\/jlr.D055020","article-title":"Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC\/MS","volume":"56","author":"Onorato","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1021\/jm5019093","article-title":"PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS","volume":"58","author":"Dahlin","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2016.05.071","article-title":"Biochemical characterization of human acyl coenzyme A: 2-monoacylglycerol acyltransferase-3 (MGAT3)","volume":"475","author":"Brandt","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152360_bib39","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1021\/jm049902r","article-title":"Deriving knowledge through data mining high-throughput screening data","volume":"47","author":"Diller","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib40","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1021\/acs.jmedchem.3c01147","article-title":"Discovery of 12 (BMS-986172) as a highly potent MGAT2 inhibitor that achieved targeted efficacious exposures at a low human dose for the treatment of metabolic disorders","volume":"66","author":"Meng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib41","article-title":"Diacylglycerol acyltransferase 1\/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice","volume":"8","author":"Takemoto","year":"2020","journal-title":"Phys. Rep."},{"key":"10.1016\/j.bbrc.2025.152360_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123322","article-title":"The many faces of DGAT1","volume":"362","author":"Oleszycka","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2025.152360_bib43","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1074\/jbc.M114.555961","article-title":"Intestine-specific deletion of acyl-CoA:monoacylglycerol acyltransferase (MGAT) 2 protects mice from diet-induced obesity and glucose intolerance","volume":"289","author":"Nelson","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152360_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2025.152360_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.bbrc.2025.152360_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.bbrc.2025.152360_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.bbrc.2025.152360_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2025.152360_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jphs.2015.06.007","article-title":"JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis","volume":"128","author":"Okuma","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2025.152360_bib50","doi-asserted-by":"crossref","first-page":"E835","DOI":"10.1152\/ajpendo.00646.2020","article-title":"GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism","volume":"320","author":"Boer","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2025.152360_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/life12010029","article-title":"Role of a dual glucose-dependent insulinotropic peptide (GIP)\/Glucagon-like Peptide-1 receptor agonist (Twincretin) in glycemic control: from pathophysiology to treatment","volume":"12","author":"Pelle","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bbrc.2025.152360_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.bbrc.2025.152360_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000233249","article-title":"UCP3 expression in liver modulates gene expression and oxidative metabolism in response to fatty acids, and sensitizes mitochondria to permeability transition","volume":"24","author":"Camara","year":"2009","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bbrc.2025.152360_bib55","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/jc.2018-01697","article-title":"Effect of macronutrient type and gastrointestinal release site on PYY response in normal healthy subjects","volume":"104","author":"Mangan","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cmet.2020.12.018","article-title":"Hypothalamic detection of macronutrients via multiple gut-brain pathways","volume":"33","author":"Goldstein","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/br.2017.890","article-title":"Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues","volume":"6","author":"Lin","year":"2017","journal-title":"Biomed Rep"},{"key":"10.1016\/j.bbrc.2025.152360_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human Primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152360_bib60","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152360_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bbrc.2025.152360_bib62","article-title":"AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbrc.2025.152360_bib63","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.152360_bib64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152360_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as modulator of metabolism in health and disease","volume":"10","author":"Tezze","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbrc.2025.152360_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.plipres.2013.12.001","article-title":"Regulation of energy metabolism by long-chain fatty acids","volume":"53","author":"Nakamura","year":"2014","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbrc.2025.152360_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPARbeta\/delta and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.bbrc.2025.152360_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2025.152360_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"Norregaard","year":"2018","journal-title":"Diabetes Obes. Metabol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25010757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25010757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:58:50Z","timestamp":1762095530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25010757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":69,"alternative-id":["S0006291X25010757"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152360","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152360"}}